MRNS insider transaction filings
MARINUS PHARMACEUTICALS, INC. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-02-11. Screen MRNS transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for MRNS between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — MARINUS PHARMACEUTICALS, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-02-11 | 4 | Ezickson Elan — Director | Disposition to issuer (D): 8,600 @ $0.55 · Disposition to issuer (D): 2,300 @ $0.55 · Disposition to issuer (D): 10,450 (derivative) @ $0 · Disposition to issuer (D): 20,900 (derivative) @ $0 · Disposition to issuer (D): 16,200 (derivative) @ $0 · Disposition to issuer (D): 12,375 (derivative) @ $0 · +2 more | EDGAR |
| 2025-02-11 | 4 | Fischer Seth H. Z. — Director | Disposition to issuer (D): 12,707 @ $0.55 · Disposition to issuer (D): 2,300 @ $0.55 · Disposition to issuer (D): 10,450 (derivative) @ $0 · Disposition to issuer (D): 20,900 (derivative) @ $0 · Disposition to issuer (D): 16,200 (derivative) @ $0 · Disposition to issuer (D): 12,375 (derivative) @ $0 · +6 more | EDGAR |
| 2025-02-11 | 4 | Hulihan Joseph — CHIEF MEDICAL OFFICER | Disposition to issuer (D): 17,155 @ $0.55 · Disposition to issuer (D): 55,570 @ $0.55 · Disposition to issuer (D): 49,125 (derivative) @ $0 · Disposition to issuer (D): 98,250 (derivative) @ $0 · Disposition to issuer (D): 115,418 (derivative) @ $0 · Disposition to issuer (D): 77,175 (derivative) @ $0 · +3 more | EDGAR |
| 2025-02-11 | 4 | Johnson Marvin — Director | Disposition to issuer (D): 5,389 @ $0.55 · Disposition to issuer (D): 7,101 @ $0.55 · Disposition to issuer (D): 10,450 (derivative) @ $0 · Disposition to issuer (D): 20,900 (derivative) @ $0 · Disposition to issuer (D): 32,400 (derivative) @ $0 | EDGAR |
| 2025-02-11 | 4 | Pfanstiel Steven — CFO AND COO | Disposition to issuer (D): 17,303 @ $0.55 · Disposition to issuer (D): 62,470 @ $0.55 · Disposition to issuer (D): 57,300 (derivative) @ $0 · Disposition to issuer (D): 114,600 (derivative) @ $0 · Disposition to issuer (D): 126,585 (derivative) @ $0 · Disposition to issuer (D): 74,475 (derivative) @ $0 · +1 more | EDGAR |
| 2025-02-11 | 4 | Shafer Christina — CHIEF COMMERCIAL OFFICER | Disposition to issuer (D): 18,778 @ $0.55 · Disposition to issuer (D): 48,628 @ $0.55 · Disposition to issuer (D): 49,125 (derivative) @ $0 · Disposition to issuer (D): 98,250 (derivative) @ $0 · Disposition to issuer (D): 78,188 (derivative) @ $0 · Disposition to issuer (D): 57,900 (derivative) @ $0 · +2 more | EDGAR |
| 2025-02-11 | 4 | Braunstein Scott — CHAIRMAN AND CEO, Director | Purchase (P): 5,933 @ $1.10 · Disposition to issuer (D): 125,064 @ $0.55 · Disposition to issuer (D): 179,536 @ $0.55 · Disposition to issuer (D): 167,825 (derivative) @ $0 · Disposition to issuer (D): 335,650 (derivative) @ $0 · Disposition to issuer (D): 360,000 (derivative) @ $0 · +6 more | EDGAR |
| 2025-02-11 | 4 | Silverstein Christine Berni — Director | Disposition to issuer (D): 9,398 @ $0.55 · Disposition to issuer (D): 4,702 @ $0.55 · Disposition to issuer (D): 10,450 (derivative) @ $0 · Disposition to issuer (D): 20,900 (derivative) @ $0 · Disposition to issuer (D): 32,400 (derivative) @ $0 | EDGAR |
| 2025-02-11 | 4 | MAYLEBEN TIMOTHY M — Director | Disposition to issuer (D): 4,600 @ $0.55 · Disposition to issuer (D): 10,637 @ $0.55 · Disposition to issuer (D): 1,660 @ $0.55 · Disposition to issuer (D): 1,660 @ $0.55 · Disposition to issuer (D): 2,300 @ $0.55 · Disposition to issuer (D): 10,450 (derivative) @ $0 · +10 more | EDGAR |
| 2025-02-11 | 4 | MANNING MARTHA E — SVP, GEN. COUNSEL & CORP. SEC. | Disposition to issuer (D): 12,186 @ $0.55 · Disposition to issuer (D): 48,077 @ $0.55 · Disposition to issuer (D): 49,125 (derivative) @ $0 · Disposition to issuer (D): 98,250 (derivative) @ $0 · Disposition to issuer (D): 74,468 (derivative) @ $0 · Disposition to issuer (D): 57,900 (derivative) @ $0 · +2 more | EDGAR |
| 2025-01-23 | 4 | Ezickson Elan — Director | Sale (S): 1,600 @ $0.54 | EDGAR |
| 2025-01-23 | 4 | Johnson Marvin — Director | Sale (S): 1,610 @ $0.54 | EDGAR |
| 2024-10-15 | 4 | MAYLEBEN TIMOTHY M — Director | Gift (G): 4,980 @ $0 · Gift (G): 1,660 @ $0 · Gift (G): 1,660 @ $0 | EDGAR |
| 2024-08-07 | 4 | Pfanstiel Steven — CFO AND COO | Sale (S): 4,657 @ $1.13 | EDGAR |
| 2024-08-07 | 4 | Shafer Christina — CHIEF COMMERCIAL OFFICER | Sale (S): 3,820 @ $1.14 | EDGAR |
| 2024-08-07 | 4 | Hulihan Joseph — CHIEF MEDICAL OFFICER | Sale (S): 4,828 @ $1.13 | EDGAR |
| 2024-08-07 | 4 | Braunstein Scott — CHAIRMAN AND CEO, Director | Sale (S): 12,145 @ $1.13 | EDGAR |
| 2024-08-07 | 4 | MANNING MARTHA E — SVP, GEN. COUNSEL & CORP. SEC. | Sale (S): 3,621 @ $1.13 | EDGAR |
| 2024-06-20 | 4 | Silverstein Christine Berni — Director | Grant/award (A): 2,300 @ $0 · Grant/award (A): 10,450 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Noonberg Sarah B. — Director | Grant/award (A): 2,300 @ $0 · Grant/award (A): 10,450 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Nochur Sara — Director | Grant/award (A): 2,300 @ $0 · Grant/award (A): 10,450 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Johnson Marvin — Director | Grant/award (A): 2,300 @ $0 · Grant/award (A): 10,450 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Fischer Seth H. Z. — Director | Grant/award (A): 2,300 @ $0 · Grant/award (A): 10,450 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Ezickson Elan — Director | Grant/award (A): 2,300 @ $0 · Grant/award (A): 10,450 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Austin Charles — Director | Grant/award (A): 2,300 @ $0 · Grant/award (A): 10,450 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Shafer Christina — CHIEF COMMERCIAL OFFICER | Grant/award (A): 10,918 @ $0 · Grant/award (A): 49,125 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Hulihan Joseph — CHIEF MEDICAL OFFICER | Grant/award (A): 10,918 @ $0 · Grant/award (A): 49,125 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Pfanstiel Steven — CFO AND COO | Grant/award (A): 12,733 @ $0 · Grant/award (A): 57,300 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Braunstein Scott — CHAIRMAN AND CEO, Director | Grant/award (A): 37,300 @ $0 · Grant/award (A): 167,825 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | MAYLEBEN TIMOTHY M — Director | Grant/award (A): 2,300 @ $0 · Grant/award (A): 10,450 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | MANNING MARTHA E — SVP, GEN. COUNSEL & CORP. SEC. | Grant/award (A): 10,918 @ $0 · Grant/award (A): 49,125 (derivative) @ $0 | EDGAR |
| 2024-03-27 | 4 | Braunstein Scott — CHAIRMAN AND CEO, Director | Option exercise (M): 50,000 @ $4.28 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2024-02-22 | 4 | Shafer Christina — CHIEF COMMERCIAL OFFICER | Sale (S): 2,153 @ $9.56 | EDGAR |
| 2024-02-22 | 4 | MANNING MARTHA E — SVP, GEN. COUNSEL & CORP. SEC. | Sale (S): 1,894 @ $9.57 | EDGAR |
| 2024-02-21 | 4 | Hulihan Joseph — CHIEF MEDICAL OFFICER | Sale (S): 2,814 @ $9.98 | EDGAR |
| 2024-02-21 | 4 | Pfanstiel Steven — CFO AND COO | Sale (S): 3,092 @ $9.97 | EDGAR |
| 2024-02-21 | 4 | Braunstein Scott — CHAIRMAN AND CEO, Director | Sale (S): 11,850 @ $9.94 | EDGAR |
| 2024-01-19 | 4 | Noonberg Sarah B. — Director | Grant/award (A): 4,600 @ $0 · Grant/award (A): 20,900 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | Johnson Marvin — Director | Grant/award (A): 4,600 @ $0 · Grant/award (A): 20,900 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | Silverstein Christine Berni — Director | Grant/award (A): 4,600 @ $0 · Grant/award (A): 20,900 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | Ezickson Elan — Director | Grant/award (A): 4,600 @ $0 · Grant/award (A): 20,900 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | Fischer Seth H. Z. — Director | Grant/award (A): 4,600 @ $0 · Grant/award (A): 20,900 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | Nochur Sara — Director | Grant/award (A): 4,600 @ $0 · Grant/award (A): 20,900 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | Austin Charles — Director | Grant/award (A): 4,600 @ $0 · Grant/award (A): 20,900 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | Shafer Christina — CHIEF COMMERCIAL OFFICER | Grant/award (A): 21,835 @ $0 · Grant/award (A): 98,250 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | Hulihan Joseph — CHIEF MEDICAL OFFICER | Grant/award (A): 21,835 @ $0 · Grant/award (A): 98,250 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | Pfanstiel Steven — CFO AND COO | Grant/award (A): 25,465 @ $0 · Grant/award (A): 114,600 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | Braunstein Scott — CHAIRMAN AND CEO, Director | Grant/award (A): 74,600 @ $0 · Grant/award (A): 335,650 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | MAYLEBEN TIMOTHY M — Director | Grant/award (A): 4,600 @ $0 · Grant/award (A): 20,900 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | MANNING MARTHA E — SVP, GEN. COUNSEL & CORP. SEC. | Grant/award (A): 21,835 @ $0 · Grant/award (A): 98,250 (derivative) @ $0 | EDGAR |
Recent 8-K events — MARINUS PHARMACEUTICALS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-02-11 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-12-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-12-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-12-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-12-10 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2024-11-15 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2024-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-10-24 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-10-02 | 8-K | 8.01 — Other Events | EDGAR |
| 2024-09-20 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MRNS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →